coteau ARQ.

KURA

Kura Oncology, Inc.
$9.61
−$0.25 (2.54%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-21%-3%+15%+32%+50%Oct 2025Oct 2026Apr 202652w high $13.9052w low $7.36
KURASPY
Wall St. Highest PT $76.00 (+690.8%) Wall St. Avg PT $31.85 (+231.4%)
$7$26$44$62$80POC $9Hi $76Avg $32
Underwater Drawdown %Max DD -39.0%Current -29.3%
0.0%-39.0%
Relative Strength vs SPY-11.5% vs SPYUnderperforming
+35%0%-35%
1W
+$0.53 (5.84%)
1M
−$1.43 (12.95%)
3M
−$0.78 (7.51%)
6M
+$0.35 (3.78%)
YTD
−$0.78 (7.51%)
1Y
+$0.51 (5.60%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
13 analysts · mean score 1.31
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$9.61
Average target$31.85
+$22.24 (+231.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$15.00
Median$31.85
High$76.00
12-month Wall Street target range

Third-party ratings, not Coteau's views.

Key stats & company

Market value$870.0M
P/E (next 12 months, estimated)-4.2
52-week range$7.36 – $13.90
Revenue growth (latest quarter vs a year ago)+36.5%
Dividend yieldNo dividend
Analyst consensusStrong Buy (13)
Average analyst price target$31.85 (+231%)

What they do

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for KURA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

Next report: –
No EPS history available.

News & catalysts

More news
No recent headlines.
Insider trades
Powl Brian T.
Chief Commercial Officer · 2026-09-29
Sell
$165.9K
Leoni Mollie
Chief Medical Officer · 2026-09-29
Sell
$309.6K
Ford Kathleen
Chief Operating Officer · 2026-09-29
Sell
$39.4K
Powl Brian T.
Chief Commercial Officer · 2026-09-28
Sell
$84.5K
Powl Brian T.
Chief Commercial Officer · 2026-09-28
Sell
$94.7K
Doyle Thomas James
SVP, Finance & Accounting · 2026-09-28
Sell
$48.4K
Leoni Mollie
Chief Medical Officer · 2026-09-28
Sell
$130.7K
Ford Kathleen
Chief Operating Officer · 2026-09-28
Sell
$72.5K
Bair Teresa Brophy
Chief Legal Officer · 2026-09-28
Sell
$88.6K
Burrows Francis
Chief Scientific Officer · 2026-09-24
Sell
$224.5K
Wilson Troy Edward
Director, President and CEO · 2026-08-24
Buy
$1.2M
Powl Brian T.
Chief Commercial Officer · 2026-08-21
Sell
$51.7K

Stats refreshed 2026-10-22 12:46:17 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026